Wormwood in Chronic Progressive Disorders With Reduced Appetite

NCT ID: NCT01126931

Last Updated: 2010-05-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-02-28

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Wormwood is approved herbal medicine for the treatment of reduced appetite in Germany (Registration No.: 1339.99.99). Reduced appetite is observed in many chronic health disorders such as old age, immune disorders and cancer.

Trial aims at observing beneficial effects of wormwood supplementation in various chronic disorders associated with reduced appetite

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Supplementation with wormwood in chronic disorders associated with reduced appetite.

Examples:

1. Cancer
2. Autoimmune diseases such as Crohns disease and IgA Nephropathy
3. Old age
4. Chronic stress and depression

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Appetite and weight loss
* Chronic progressive disease

Exclusion Criteria

* Life expectancy less than 3 months
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Freiburg

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Medical Faculty, University of Saarland, Homburg, Germany

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Simone S Krebs, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Freiburg, Nuclear Medicine, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Freiburg, Medical Faculty

Freiburg im Breisgau, Baden, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Simone S Krebs, MD, Ph.D

Role: CONTACT

(+49) -761-27-3913

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Simone S Krebs, MD, PhD

Role: primary

(+49) -761-27-3913

References

Explore related publications, articles, or registry entries linked to this study.

Omer B, Krebs S, Omer H, Noor TO. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study. Phytomedicine. 2007 Feb;14(2-3):87-95. doi: 10.1016/j.phymed.2007.01.001. Epub 2007 Jan 19.

Reference Type BACKGROUND
PMID: 17240130 (View on PubMed)

Krebs S, Omer TN, Omer B. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease - A controlled clinical trial. Phytomedicine. 2010 Apr;17(5):305-9. doi: 10.1016/j.phymed.2009.10.013. Epub 2009 Dec 3.

Reference Type BACKGROUND
PMID: 19962291 (View on PubMed)

Krebs S, Omer B, Omer TN, Fliser D. Wormwood (Artemisia absinthium) for poorly responsive early-stage IgA nephropathy: a pilot uncontrolled trial. Am J Kidney Dis. 2010 Dec;56(6):1095-9. doi: 10.1053/j.ajkd.2010.06.025. Epub 2010 Sep 16.

Reference Type DERIVED
PMID: 20843592 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Appetite and Weight Loss

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Herbal Extract Study
NCT02095301 COMPLETED NA
Hemp Seed Awareness
NCT04841954 RECRUITING NA